



Biweekly Update 13-March 2020

StrokeNet Enrollment Update

ARCADIA	437/1100	CREST 2	1642/2480
Sleep SMART	247/3062	CREST H	138/500
TRANSPORT2	11/129	MOST	33/1200
I-ACQUIRE	22/240	ARCADIA-CSI	47/500
ASPIRE	0/700	SATURN	0/1480

StrokeNet Trial Updates



Thank you all and safety first!

We have emailed some ARCADIA-specific research and COVID-19 guidelines to the PIs and PSCs at all our sites – please share with your teams to make sure that we keep the ARCADIA subjects and study teams safe and engaged.

As of March 12, 2020, 1697 participants have been consented and 437 participants randomized at 100 sites (of 144 sites that have been released to enroll). This is an increase of 40 consented and 10 subjects randomized in a bit less than two weeks. Our enrollment is at 39.7% of the overall goal.

Thank you to the 26 sites that consented (many multiple times) and 5 sites that randomized subjects in the last two weeks. A special thanks to the University of Kentucky Hospital and the Hospital of the University of Pennsylvania for randomizing twice during the past two weeks!

We have now released to enroll a total of 144 sites, 134 are active, and we are still working on adding other qualified sites to the ARCADIA roster. We have gotten final approvals and contracts for our Canadian colleagues to join as well! We have quite a few sites working towards being released to enroll. However, please let us know of any excellent stroke sites that are interested in participating in this important trial.

Please keep approaching ESUS patients about the ARCADIA trial at your sites. Remember, every site's best effort is necessary for the trial to succeed!

Webinar: Our next PI and coordinator webinar will be March 24th at 2 PM Eastern--save the date! We're asking that at least 1 person from each site attend the monthly webinar and pass the information along to their team. Also, please send suggestions for topics you'd like discussed.

If you miss out on a webinar, you will soon be able to find the slides on the StrokeNet website (<https://nihstrokenet.org/intranet/minutes/trial-webinars>).



February was a fantastic month for Sleep SMART randomizations as was the first week of March!

As of March 11, 2020, 740 subjects have been enrolled and 247 subjects have been randomized.

The following sites remain at the top of our leader board for the most randomizations:

1. Brooks Rehabilitation Hospital, Jacksonville, FL-Parag Shah, MD and Taisiya Matev-26 subjects randomized
2. Moses H. Cone Memorial Hospital, Greensboro, NC-Pramod Sethi, MD, Rizwan Sabir, and Glynda Reaves-16 subjects randomized
3. Prisma Health Midlands (Palmetto Health), Columbia, SC-Souvik Sen, MD and Phil Fleming-15 subjects randomized
4. Sarasota Memorial Hospital, Sarasota, FL-Mauricio Concha, MD and Jeanette Wilson-13 subjects randomized

There is a 2-way tie for 5th place between the following sites:

- Barnes Jewish Hospital, St. Louis, MO-Eric Landsness, MD, Will Holt, and Jill Newgent-11 subjects randomized
- University of Cincinnati, Cincinnati, Ohio-Sheva Coleman, MD and Sadie Caldwell-11 subjects randomized

Congratulations to the following two sites for randomizing their first subject in March:

1. University of Nebraska Medical Center, Omaha, NE-Pierre Fayad, MD and Shellie Neuman
2. St. Mary's Medical Center, Grand Junction, CO-Logan McDanel, MD and Lisa Bertrand

Don't forget these important reminders:

1. KOEO and WebDCU do **NOT** communicate. Subjects should be always be added in WebDCU first! This will produce a subject ID that will then need to be entered in KOEO.
2. **All components** of the 3- and 6-month outcome assessments should be conducted by a **blinded** study team member.
3. Please use the informed consent checklist for every new subject enrollment. This checklist is available on our website: <https://www.nihstrokenet.org/sleep-smart-trial/research-team>.
4. Please remember to enter all subjects who meet criteria for enrollment, but decline participation, into WebDCU under Study Progress tab > Screen Failure Report.
5. Please remember to report AEs. If you need guidance, please refer to the Sleep SMART MOP. Please recall that the only AEs that should be reported between consent and randomization are:
 - All SAEs (fatal and non-fatal) that are definitely related or stand a reasonable possibility to be related to the Nox T3 sleep apnea test or the aCPAP run-in night procedures (within 5 days of awareness of event for non-fatal; within 24 hours of awareness for fatal)
 - All non-serious AEs of special interest (see protocol 8.3.8) that are definitely related or stand a reasonable possibility to be related to the Nox T3 sleep apnea test or the aCPAP run-in night procedures (within 5 days of awareness of event)
 - Primary outcome events (ischemic stroke, ACS, and deaths) (within 5 days of awareness of event)
6. All responses to Data Clarification Requests (DCRs) must be submitted within 5 days of query generation, except those associated with Serious Adverse Events, which must be answered within 24 hours of query

generation. Site payments are contingent upon the subject's data being entered, submitted, and all DCRs addressed.

7. Please review the Data Collection Guidelines for Sleep SMART located in project documents in WebDCU for how to complete CRFs. This should be the first place you look when you are not sure how to complete a form.
8. If the window for the 3-month visit ends and you have not been able to reach a subject, please continue to reach out to them until the 6-month window begins.
9. Don't forget to collect the IQCODE. This assessment should not be done by the patient. It should be completed by someone close to the subject.
10. The baseline NIH Stroke Scale should be done after the subject is enrolled.
11. For stroke outcome events, please be sure to upload documentation in the outcome packets that provides information about new stroke symptoms, including focal neurological symptoms and signs on exam, and associated dates.
12. Please attempt to have a "warm" hand-off of intervention subjects with FusionHealth prior to discharge. Help facilitate a call from the intervention subject to Fusion (470-655-6688), and remind subjects that they can save the phone number in their contacts.
13. Please remember to upload all CIRB Modification Letters to WebDCU in the CIRB Approved Administrative Amendments space holder.
14. All required site and people documents, including training, will need to be completed and uploaded in WebDCU before your site can be released to enroll. **Please continue to work diligently with your study teams on missing, expired or rejected documents.**

Save the dates-Our next PI and coordinator webinar will be Monday, March 23, 2020 from 1-2 EST. Unfortunately, due to COVID-19 we must cancel the April 16, 2020 hands-on FusionHealth workshop. We plan to reschedule it at a later date.



Site Startup and Enrollment Updates:

sites: **54;**

enrollments: **138**

We are at to **138** patients, **39%** of our target, and have begun to accumulate 1-year follow up scans. Let's keep the enrollment going!

We had an interesting discussion on our weekly Collaborative study conference call about how the COVID-19 outbreak may affect recruitment in CREST-2 and CREST-H. Some local IRBs are surveying projects to determine whether there should be a pause in activity to limit contact in clinical settings. We argued that many randomized clinical trials have potential benefit to patients and therefore should not be paused. Further discussion is expected. For now we are continuing recruitment efforts nationwide, with appropriate precautions in place.

We are still recruiting additional sites. Contact Randy Marshall rsm2@columbia.edu, Ron Lazar rlazar@uabmc.edu, Jaya Vijayan vijayan.jaya@mayo.edu, or Kevin Slane KJS4@columbia.edu with any questions.



We have **8** sites that are released to enroll and a total of **22** randomized subjects:

- Ann Arbor, MI - C.S. Mott Children's Hospital - **1** participant randomized
- Boston, MA - Boston Children's Hospital - **7** participants randomized
- Cincinnati, OH - Cincinnati Children's Hospital Medical Center - **3** participants randomized
- Columbus, OH - OSU Martha Morehouse Medical Plaza- **1** participant randomized
- La Jolla, CA – USCD Health La Jolla – **4** participants randomized
- New Haven, CT - Yale New Haven Children's Hospital - **2** participants randomized
- Philadelphia, PA - Children's Hospital Of Philadelphia (CHOP)
- Roanoke, VA - Fralin Biomedical Research Institute - **4** participants randomized

Thank-you to all the sites they have been working hard!

Save the date – Our next PI/Co-I/Coordinator Webinar will be Thursday 19 March (12-1pm ET).

Special Note: Please be sure you check your e-mail from Max Mays (sent 3/10/2020) as he sent out, on behalf of The I-ACQUIRE Operations Committee, a document to all site PIs and Primary Study Coordinators to provide guidance regarding the COVID-19 situation. If you need a copy please let Max Mays (maysmw@ucmail.uc.edu) know.



Big thank you to all the sites who submitted their continuing review. The documents have been submitted to the cIRB and the continuing review is in process.

As of March 11, 2020, 47 subjects have been enrolled in CSI. Thank you to all of our sites who are working hard to get their CTAs and regulatory documents in.

The study team would like to give a shout out to our top 3 enrolling sites:

University of Iowa
Greenville Hospital System
University of Texas Health Science San Antonio and MUSC

Thank you to all the sites that have consented and enrolled subjects over the past 2 weeks.

Congratulations to the new sites who are released to enroll:

- ✓ Intercoastal Medical Group
- ✓ UF Health Shands Hospital
- ✓ University of Wisconsin University Hospital
- ✓ Intermountain Medical Center

We now have 51 sites who have been released to enroll.

Important Reminders

- Please remember when you are seeing your ARCADIA subjects, don't forget about CSI!
- When a subject declines, state the reason in WebDCU

Please contact Tashia Harris, herndotl@ucmail.uc.edu or Stephanie Kemp, skemp@stanford.edu with any questions.



ASPIRE

- 82 executed CTAs and 77 sites with cIRB approval
- 25 sites released to enroll
- The May 6-7 ASPIRE/SATURN Investigator Meeting will be rescheduled due to COVID-19 and travel restrictions
- The 1st ASPIRE Webinar will take place on 4/22/20 3-4pm EST
 - Call in details will be sent in April
- WebDCU Pointers for First Study Drug Shipment:
 - Enter address and contact person for study drug shipments in SITE MANAGEMENT>CLINICAL SITE
 - If you are using a pharmacy, upload Institutional Pharmacy License in Site Regulatory Documents and enter person with Pharmacist role on your DOA
 - If you are not using a pharmacy, waive Institutional Pharmacy License in Site Regulatory Documents and enter a note in your DOA, be sure a person has been assigned study drug dispensing (J) and accountability (I) roles
- Site Readiness Calls should be scheduled if your CTA and cIRB approval are in place
 - New dates have been added to the online poll: <https://doodle.com/poll/rnnu37hfvmc>



- Congratulations to Dr. Creed Pettigrew and Patricia Arnold at **The University of Kentucky Hospital**, Lexington, KY for randomizing their first subject!
- Congratulations to the following sites that have both randomized **2** subjects so far in March!
 - **Fairview Southdale Hospital**, Edina, MN
 - Dr. Oladi Benthoo and Megan Tessmer
 - **Central DuPage Hospital**, Winfield, IL
 - Dr. Kapil Sachdeva and Jennifer (Robin) Schmidt
- Congratulations to the following sites that have been released to enroll since our last update!
 - **Ochsner Medical Center**, New Orleans, LA
 - Dr. Ifeanyi Iwuchukwu and Stephen Fletcher
 - **Baylor University Medical Center**, Dallas, TX
 - Dr. Rashedul Hasan and Jon Thammavong
 - **OSU Wexner Medical Center**, Columbus, OH
 - Dr. Deepak Gulati and Luke Herren
 - **St. Louis University Hospital**, St. Louis, MO
 - Dr. Randall Edgell and Andre Guthrie
 - **Rush University Medical Center**, Chicago, IL
 - Dr. Alejandro Vargas and Drew Simon

As of 13-Mar-2020, there are **33 subjects** randomized and **52 sites** released to enroll, **17** of which have enrolled at least one subject.

The PI hotline is available 24/7 for eligibility, safety or enrollment questions: 1-833-229-MOST

Thank you all for your efforts!



SATURN is very excited to begin enrollment next week! Several sites have both fully executed CTAs and CIRB approval and are currently being scheduled for Readiness calls.

Regulatory documents that required site action were due to be returned and uploaded to WebDCU™ by January 24th 2020. **Please address any outstanding regulatory documents at your site as soon as possible.**

RCC coordinators should follow up on all outstanding CTAs at this time. It is important to get your sites ready for release to enroll!

- Protocol Training is available in WebDCU™ toolbox and on WebDCU Training Campus <https://webdcu.musc.edu/campus/>
- Study documents are available in WebDCU™ toolbox: including regulatory documents, regulatory parameters document, training materials, DRAFT CRFs, protocol appendices, Provider Information Sheets, Participant Information Sheets and MOP
- Reminder to **enter site address** into WebDCU™ for supplies: Site Management>Clinical Site>click on your site to edit and enter address
- Reminder to complete and submit site DOA in WebDCU™
- Reminder to upload Regulatory documents into WebDCU™

If you have any questions regarding start-up please reach out to these contacts at the NCC:

Kimberlee Bernstein Project Manager gammk@ucmail.uc.edu

Wren Hanson Contracts hansonwm@ucmail.uc.edu

Emily Stinson Regulatory stinsoey@ucmail.uc.edu


Jen Golan Regulatory golanjl@ucmail.uc.edu



Reminder that our next PI and Coordinator call is scheduled for **Monday, March 16th at 11am ET**. If anyone has topics they would like to discuss during the call, please send them to Max Mays (max.mays@uc.edu).

Moss Rehab, University of Kentucky, University Southern California, Medstar, Emory University, and University of Cincinnati continue to enroll. MUSC, Barnes Jewish, Burke, University of Texas, University Alabama, and Baystate open to enrollment! There are eleven subjects randomized in the trial. Two are in the intervention phase. Four have completed the study, five completed the intervention phase and are in the follow-up period. There are several patients being screened or scheduled for screening this month. Duke has received CIRB approval and we are working on adding UPMC and the Cleveland VA to the trial. They are working toward IRB approval. Keep the randomizations coming, TRANSPORT2 team!

From the CREST-2 Clinical Coordinating Center:

	CREST-2		CREST-2 StrokeNet
	CEA	868	378 (44% of total)
	CAS	782	133 (17% of total)
	Total	1650	511 (31% of total)

Congrats to our CREST-2 partners at the University of Minnesota, the University of Washington, and Vanderbilt University for being the first StrokeNet sites to randomize this month!



Continuing Review: It is time again to submit the CIRB continuing review for CREST-2. If you have received CIRB approval, the continuing review documents need to be submitted to the CIRB by **March 27th**. If you do not have CIRB approval yet, please disregard this message.

Please be on the lookout for an email from the CCC that outlines the required documents needed, which includes:

1. Updated StrokeNet COI forms from both CREST-2 and CREST-H team members
2. Completed research site continuing review form
3. De-identified copy of the last signed informed consent form
4. Current eDOA log generated and printed from WebDCU

The email will include additional information regarding these documents, as well as relevant attachments. These required documents will need to be submitted to your site manager by March 27th, who will then submit to the CIRB on your behalf.

Please note that due to the continuing review, the deadline for other submissions (adding/removing personnel, site specific consent changes, etc.) is **March 20, 2020**.

NIH StrokeNet COVID-19 Guidance

The current public health crisis is evolving very quickly, and NIH StrokeNet leadership has prepared guidance in regard to the novel Coronavirus. Due to the importance of the information, it will be sent under separate cover. Please watch your email. StrokeNet specific trials will communicate individual guidance to their teams. Trial related questions should be addressed to the PI or Project Manager, however, always feel free to contact the NCC. Please see the CDC and WHO links below for more information on keeping safe and promoting safety during this time.

Coronavirus Disease 2019 (COVID-19) Information for NIH Applicants and Recipients

The NIH is deeply concerned for the health and safety of people involved in NIH research, and about the effects on the biomedical enterprise in the areas affected by the HHS declared [public health emergency for COVID-19](#). Due to the potential exceptional impact, we want to assure our recipient community that NIH will be doing our part to help you continue your research. This is a rapidly evolving situation and we will provide updated guidance and information as it becomes available.

Guidance

- [NIH Late Application Policy Due to Public Health Emergency for United States for 2019 Novel Coronavirus \(COVID-19\) - NOT-OD-20-082](#)
- [General Frequently Asked Questions \(FAQs\) - Proposal Submission and Award Management Related to COVID-19 - NOT-OD-20-083](#)
- [Flexibilities Available to Applicants and Recipients of Federal Financial Assistance Affected by COVID-19 - NOT-OD-20-086](#)
 - [COVID-19 Flexibilities for Applicants and Recipient FAQs](#)

Resources

- [NIH Website: Coronavirus Disease 2019 \(COVID-19\)](#)
- [CDC Website: Coronavirus Disease 2019 \(COVID-19\)](#) including its guidance for [Institutes of Higher Education](#) and [CDC Website: Centers for Disease Control \(CDC\)](#)
- [WHO Website: Coronavirus disease \(COVID-19\) outbreak](#)
- [General Information on NIH Extramural Response to Natural Disasters and Other Emergencies](#)

Congratulations!

ASA Outstanding Stroke Research Awards

February 2020

On February 18, 2020, eleven leading scientists who've devoted their careers to stroke research, as well as authors of notable new research, were honored for their work by the American Stroke Association. The awards were given during the American Stroke Association's International Stroke Conference 2020 in Los Angeles, a world premier meeting for researchers and clinicians dedicated to the science of stroke and brain health.

The NIH StrokeNet was honored to have THREE of our own RCC MPIs receive these distinguished awards:

Congratulations to:

RCC 16 University of Miami MPI:

Ralph L. Sacco, M.D., M.S., FAHA, University of Miami Miller School of Medicine, Miami, Florida, received the inaugural **Edgar J. Kenton III Lecture Award**.

Dr. Sacco, the 2020 winner of the new Edgar J. Kenton III Lecture Award, is the Olemberg Family Chair in Neurological Diseases; Miller Professor of Neurology, Public Health Sciences, Human Genetics and Neurosurgery; chairman, department of neurology; senior associate dean for clinical and translational science, Miller School of Medicine, University of Miami; chief of neurology service, Jackson Memorial Hospital; and executive director, Evelyn F. McKnight Brain Institute in Miami, Florida. Sacco also served as American Heart Association President from 2010-2011.

RCC 17 University of Michigan MPI:

Devin L. Brown, M.D., FAHA, University of Michigan, Ann Arbor, Michigan, who will receive the **Stroke Research Mentoring Award**

Dr. Brown, the recipient of the 2020 Stroke Research Mentoring Award, is professor of neurology and director of the vascular neurology fellowship program at the University of Michigan Medical School in Ann Arbor, Michigan. The Stroke Research Mentoring Award recognizes outstanding achievements in mentoring future generations of stroke researchers.

RCC 27 Wake Forest MPI:

Pamela W. Duncan, Ph.D., P.T., FAHA, Wake Forest Baptist Health, Winston Salem, North Carolina, who will receive the **David G. Sherman Lecture Award** for lifetime contributions to investigation, management, mentorship and community service in the stroke field.

Dr. Duncan, the 2020 winner of the David G. Sherman Lecture Award, is professor of neurology and professor in gerontology and geriatric Medicine at Wake Forest Baptist Health in Winston Salem, North Carolina. The Sherman Award honors David G. Sherman, M.D., a prominent stroke physician and an internationally recognized leader and researcher in stroke prevention and treatment. The award recognizes lifetime contributions to the investigation, management, mentorship and community service in the stroke field.

Steering Committee Call

*Steering Committee Calls are a requirement for all NIH StrokeNet RCCs
(one representative per RCC required)*

The next Steering Committee call will be the annual STROKENET NETWORK WEBINAR. The webinar will be held on **Wednesday, 8-April, 2020, from 12 noon – 3:00 pm ET**. Dial in: 513-621-0220; 1-877-621-0220; Passcode 434578.

To join the meeting: <https://nihstrokenet.adobeconnect.com/network/>

Note, you must also dial in to join the conversation.

Coordinator Webinar

Coordinator Webinars are a requirement for the NIH StrokeNet RCC Coordinators/Managers

Wednesday, March 25, 2020 - 1:30 PM ET

Topic: NCC & NDMC – ICF Reminders and Changes to the WebDCU™ Unanticipated Event Reporting Module

Presenters: TBD

Moderator: David Haney, RT, Case Western Reserve University

To join the meeting: <https://nihstrokenet.adobeconnect.com/coordinator/>

Please enter as a guest, then your email address or your first and last name.

To take part in the conversation you MUST dial in. (877) 621-0220; Passcode: 434578

Professional Development Webinar

Professional Development Webinars are a requirement for the NIH StrokeNet Trainees

Monday, March 16, 2020

Presenters:	11:30	Joy Buie, PhD, MSCR Carotid-femoral Pulse Wave Velocity is Associated with Trail Making Test A and B Scores in Whites but not African Americans aged 40-75
	12:00	Andrew Tesla DeMarco, PhD, CCC-SLP Functional Anomaly Mapping in Chronic Stroke Aphasia
	12:30	Pouria Moshayedi, MD, PhD Visual Aids for Patient, Family, and Physician Decision Making About Late Imaging-Guided Endovascular Thrombectomy for Acute Ischemic Stroke

Moderator: **Harold Adams, MD**

To join the meeting: <https://nihstrokenet.adobeconnect.com/pdw/>. Please enter as a guest, then your email address or your first and last name.

To take part in the conversation you MUST dial-in. (877) 621-0220 Passcode: 190825

Grand Rounds

Grand Rounds are a requirement for the NIH StrokeNet Trainees, however all are welcome to participate.

Thursday, March 26, 2020 - 4:00 PM ET

Topic: Gloves Off for Acute Stroke Management: Fellow Case Presentation to Two Stroke Experts

Experts: **Christine Holmstedt, DO** – Medical University of South Carolina
Brett Meyer, MD – University of California San Diego

Case Presenters: TBA

To join the meeting: <https://nihstrokenet.adobeconnect.com/grandrounds/>. Please enter as a guest, then your email address or your first and last name.

To take part in the conversation you MUST dial-in. (877) 621-0220 Passcode: 190825

StrokeNet Regulatory Update

Site Binder Guidance for StrokeNet Studies:

The NIH StrokeNet National Coordinating Center has the following Standard Operating Procedures related to maintaining and storing onsite regulatory binders:

- ADM 2 Reporting COI and Financial Disclosures
- ADM 16 Network Process for Trial “Master” and “Site” Regulatory file Management
- ADM 21 Regulatory and Clinical Data Maintenance and Data Storage
- GCP 12 Regulatory and Clinical Trial Data Maintenance Storage

These SOPs can be found on the StrokeNet Website - https://nihstrokenet.org/sop_gcp. Please take a few minutes to review these SOPs. Feel free to contact Jen Golan (golanjl@ucmail.uc.edu) or Emily Stinson (stinsoey@ucmail.uc.edu) with any questions. Thank you!

NIH StrokeNet Employment Opportunities

University of Cincinnati Vascular Neurologist

The Department of Neurology and Physical Medicine and Rehabilitation at the University of Cincinnati has new, exciting opportunities for **Vascular Neurologists** at Assistant, Associate, or Professor levels on both clinical and research career tracks.

The candidate will join an internationally renowned stroke program that includes:

- A highly collaborative, multidisciplinary team of 9 Vascular Neurologists, 7 Emergency Medicine Stroke Specialists, 9 Neurocritical Care Intensivists, 3 Interventionalists from Neurosurgery and Neurology, 2 Cerebrovascular Neurosurgeons, 6 Neuroradiologists, a large cohort of extremely experienced Research Coordinators, among others
- A JCAHO-Certified Comprehensive Stroke Center, including a 20-bed Neuroscience Intensive Care Unit and 10-bed variable acuity unit
- Multicenter, high-volume approach to acute stroke treatment and trial enrollment (550+ treated with reperfusion therapies in 2019), including a newly activated Mobile Stroke Unit
- A large, NIH-funded stroke research program, ranging from clinical trials in treatment, prevention, and rehabilitation/recovery, to epidemiology studies in health disparities and brain health, to molecular genetics
- A home to the National Coordinating Center (NCC) and a Regional Coordinating Center (RCC) of the NIH StrokeNet

The clinical practice would consist of a personally tailored combination of inpatient service, acute stroke call (including telemedicine), outpatient clinic, and teaching of residents and fellows from several different disciplines.

Exciting collaborative research opportunities are available for participation and growth, but not required.

MINIMUM QUALIFICATIONS: Must have an MD or DO, completed an ACGME-approved Vascular Neurology fellowship program, and be BE/BC.

HOW TO APPLY: Contact Pooja Khatri, MD, Director of the Vascular Neurology Division: pooja.khatri@uc.edu

The University of Cincinnati, as a multi-national and culturally diverse university, is committed to providing an inclusive, equitable and diverse place of learning and employment.

StrokeNet National Coordinating Center Project Manager - FASTEST

The NIH StrokeNet NCC is looking for a Project Manager for the FASTEST trial – a global trial -- spanning the U.S., Canada, Germany, Spain, the U.K., and Japan; approximately 130 sites, including mobile stroke units; and approximately 860 subjects -- evaluating the use of recombinant factor VIIa to treat patients with spontaneous intracerebral hemorrhage within two hours of stroke onset/last known well. The trial will utilize exception from informed consent.

For detailed information about the position, and to apply, please visit <https://jobs.uc.edu/> and reference requisition number 44802.

For more information about StrokeNet employment opportunities, please visit

<http://nihstrokenet.org/education/employment-opportunities>

Contact: Jamey Frasure, PhD, RN, Director · NIH StrokeNet Coordinating Center · frasurjs@ucmail.uc.edu · 513-558-1742/<https://www.nihstrokenet.org>